AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02642549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Girls for Health
Description: The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development.
Study NCT01913587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
Study NCT01913587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve block
Description: Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
Study NCT01913587 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
Study NCT01450904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps incision < 2 cm
Description: MIS-TKA was performed with less than 2 cm Quadriceps incision length
Study NCT01450904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps incision 2-4 cm
Description: MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
Study NCT01450904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadriceps incision > 4 cm
Description: MIS-TKA was performed with more than 4 cm Quadriceps incision length
Study NCT01325220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: 5 mg bid
Study NCT01325220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: 10 mg bid
Study NCT01325220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: arbaclofen
Description: 10 mg tid
Study NCT01325220 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tid
Study NCT02524600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: myocardial IQ-SPECT imaging applied to scintigraphic imaging
Study NCT02524600 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scintigraphic imaging
Study NCT04065165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Ethyl
Description: 250 mg TID orally
Study NCT04065165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanreotide
Description: 120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
Study NCT04065165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: 120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh
Study NCT04456153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Continued standard of care therapy together with an oral dose of 1500 mg atovaquone twice daily (administered with a meal or snack) for up to 10 days
Study NCT04456153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Continued standard of care therapy together with matching placebo
Study NCT02905396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation
Description: implantation of spinal cord stimulator
Study NCT02398994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylprednisolone
Study NCT02398994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Methylprednisolone
Study NCT02398994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulin
Study NCT04173598 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Adaptation Training for Caregivers (CAT Famille)
Description: Family CAT manual, with a module each week to be read according to the patient's objectives and a 15-minute webcam feedback by the psychologist.
Study NCT04173598 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Psycho-education manual, with a weekly reading module and a 15-minute webcam feedback by the psychology student.
Study NCT03848871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Enstilar foam applied to affected area once daily
Study NCT03158402 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Prehabilitation with inspiratory muscle training
Description: 3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
Study NCT02912663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil and Magnesium Sulfate
Description: Single dose strategy will be used
Study NCT02912663 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single matching dosing strategy will be used
Study NCT03601871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .
Study NCT03601871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
Study NCT03601871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4
Study NCT03601871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-HT3 antagonists
Description: Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
Study NCT03601871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists
Description: Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3
Study NCT02918084 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Anastrozole or Letrozole or Exemestane
Description: Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
Study NCT02918084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole or Letrozole or Exemestane
Description: Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
Study NCT02623179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culture versus Molecular diagnostics
Description: Treatment based on the results of the FH C \& S testing - Odd Numbers on randomization table
Study NCT03127631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor
Description: Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >130mmHg, or other blood pressure lowering medication as applicable.
Study NCT04233489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Description: FNI is a family based intervention that facilitates and strengthens the mother-infant emotional connection through a structured guided interaction by a physician.~The mother is asked to sit with her baby in her arms so that they are face-to-face, and when the baby becomes restless, the physician will coach the mom to bring the baby back to a calm state. The mother will also be encouraged to verbalize her feelings to her baby. Mother-infant emotional connection is known to affect various developmental processes and improve overall health. FNI was previously shown to be efficacious in improving several long-term health outcomes in preterm infants in the neonatal intensive care unit (NICU).
Study NCT03737825 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized gaming rehabilitation Program 1
Description: Brain training games displayed on a large screen paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching in place.
Study NCT03737825 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Computerized gaming rehabilitation Program 2
Description: Brain training games displayed on a tablet device paired with physical exercise component. The program involves movements such as reaching, stepping, or stretching.
Study NCT01649700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous adipose-derived mesenchymal stem cells
Description: Patients will receive five infusions, one month apart, each comprising 5-7x10\^7 cells of autologous adipose-derived mesenchymal stem cells.
Study NCT03669978 — intervention group
Intervention type: PROCEDURE
Intervention: Creation of a bone and arterial panorama using EndoNaut® software.
Description: The routine care procedure begins with staged injections of contrast medium to provide a map of the lesions. The lesions are then treated by angioplasty with or without stenting.~New injections of contrast product are made to control the results of the treatment.~As part of this pilot study, the assistive software and its interface will be linked and with the mobile C-arm X-ray system. Scopic images and angiograms will be retransmitted to be processed by the EndoNaut® software.
Study NCT03698201 — intervention group
Intervention type: OTHER
Intervention: Non-interventional
Description: Translational, observational study
Study NCT02852525 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Confocal laser endomicroscopy (pCLE)
Description: Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
Study NCT02479347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
Study NCT02479347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine
Description: Preoperative skin preparation with povidone-iodine 10% aqueous solution
Study NCT01562028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Patients will be treated with erlotinib, 150 mg p.o., daily
Study NCT01562028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
Study NCT03537664 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Root canal preparation
Description: First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
Study NCT03537664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root canal preparation
Description: First endodontic treatment session includes the root canal preparation with Reciproc System and NaOCl 2.5%, followed by final irrigation protocol using activation techniques: XP Endo-Finisher and ultrasonic activation.
Study NCT03537664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracanal medication
Description: The second endodontic treatment includes the intracanal medication with calcium hydroxide paste, followed by an 2nd-visit root canal preparation
Study NCT01082276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lurasidone HCl
Description: 40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
Study NCT01479348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]-5-FLUORO-2'-DEOXYCYTIDINE
Description: 18FdCyd radiotracer
Study NCT03109912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized-Coaching Interventions
Description: At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
Study NCT03109912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Messages
Description: Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
Study NCT03109912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Exercise Tutorials
Description: Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
Study NCT03109912 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support and Peer Challenges
Description: Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
Study NCT00466492 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sedation or no sedation during mechanical ventilation
Description: No sedation to critically ill patients
Study NCT04066764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: 15mg twice daily for 3 weeks after operation, later 20mg once daily until 3 months after the filter is removed. Application: oral
Study NCT04066764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: 3mg for 5 days after the operation, later 0.75mg to 18mg depending on INR (2.0-3.0) until until 3 months after the filter is removed. Frequency: once daily Application: oral
Study NCT04066764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin
Description: Dose: 1mg/kg Duration: 5 days after the operation Frequency: twice daily Application: subcutaneous
Study NCT03273569 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDI-UC protocol
Description: Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
Study NCT03088085 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-mobilization
Description: Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
Study NCT03088085 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
Study NCT00533091 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-545
Description: MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.~Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks.
Study NCT00533091 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.~Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.~Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks.
Study NCT01453387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2015103B
Description: Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
Study NCT01453387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC2015103B
Description: Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
Study NCT02680678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colloid Preload
Description: preload infusion
Study NCT02680678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colloid co-load
Description: co-load infusion
Study NCT02680678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid preload
Description: preload infusion
Study NCT02680678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Crystalloid Co-load
Description: co-load infusion
Study NCT03954678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: For the first two days after their pre-operative visit, participants will be asked to continue their present level of exercise and activity, which will be monitored by pedometer. Participants will begin the activity intervention on study Day 3. Participants will be instructed to take 10,000 steps per day, recording their daily steps with a pedometer. Participants also will be provided with resistance bands and instructed on how to safely perform 10 whole-body strength training exercises. They will be instructed to perform the exercises once per day, three days a week. Participants will complete the exercise intervention until they have surgery, which is typically 12 to 48 days after the pre-operative visit.
Study NCT03954678 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Group
Description: Participants in the nutrition group will be provided with a liquid over-the-counter nutrition supplement (i.e. Boost or Ensure) to consume. Participants will be instructed to consume 1 bottle, 2 times per day, beginning 5 days before surgery and continuing 5 days post-operatively.
Study NCT03443947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue depressor group
Description: using a tongue depressor to assess airway score without tongue protrusion
Study NCT03443947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: control group
Description: airway assessment after tongue protrusion
Study NCT01479348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine intravenous (IV)
Description: Total dose of THU = 350 mg/m\^2, IV
Study NCT02202330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Video Arm
Description: 1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions.
Study NCT02202330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Arm
Description: 1. 5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)~2. Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.~3. Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions.
Study NCT01479348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrouridine (oral)
Description: Total dose of THU is 3000 mg, oral
Study NCT01479348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)/Computed tomography (CT)
Description: One prior CT and 3 sequential whole body PET